Base de dados : MEDLINE
Pesquisa : C04.588.448.200 [Categoria DeCS]
Referências encontradas : 1568 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 157 ir para página                         

  1 / 1568 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773925
[Au] Autor:Visconte V; Przychodzen B; Han Y; Nawrocki ST; Thota S; Kelly KR; Patel BJ; Hirsch C; Advani AS; Carraway HE; Sekeres MA; Maciejewski JP; Carew JS
[Ad] Endereço:Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
[Ti] Título:Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms.
[So] Source:Leukemia;31(2):505-510, 2017 02.
[Is] ISSN:1476-5551
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Autofagia/genética
Neoplasias da Medula Óssea/genética
Mutação
[Mh] Termos MeSH secundário: Genes Supressores de Tumor
Seres Humanos
Transtornos Mieloproliferativos/genética
[Pt] Tipo de publicação:LETTER; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180310
[Lr] Data última revisão:
180310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1038/leu.2016.295


  2 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29273914
[Au] Autor:Shao H; Cen J; Chen S; Qiu H; Pan J
[Ad] Endereço:Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, People's Republic of China.
[Ti] Título:Myeloid neoplasms with t(12;22)(p13;q12)/MN1-EVT6: a systematic review of 12 cases.
[So] Source:Ann Hematol;97(3):417-424, 2018 Mar.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:t(12;22)(p13;q12) is a rare but recurrent chromosomal abnormality involving the ETS transcription factor ETV6 and meningioma 1 (MN1) genes. In this study, we analyzed the clinical, cytogenetic, and molecular features of five new patients with the t(12;22)/MN1-EVT6 who presented with acute myeloid leukemia or chronic myelomonocytic leukemia. We subsequently reviewed the literature and identified seven additional cases reported with t(12;22)/MN1-EVT6. Our data suggest that neoplasms carrying the t(12;22)/MN1-ETV6, although rare, can commonly present as myeloid neoplasms at the initial diagnosis, including acute myeloid leukemia (n = 8), myelodysplastic syndrome (n = 2), and myelodysplastic/myeloproliferative neoplasms (n = 2). There were five men and seven women with a median age of 43 years (range, 15-63 years) at initial diagnosis. Cytogenetics revealed t(12;22) as the sole abnormality in five patients, with the remaining seven patients harboring additional chromosomal aberrations. Of the five patients who received known therapy regimens, all of them had poor response to the idarubicin/mitoxantrone + cytarabine regimen. Of the seven patients with follow-up information, six patients died with a median overall survival time of only 5 months (range, 1-12 months) after the emergence of t(12;22). In summary, patients with t(12;22) are frequently associated with myeloid neoplasms, poor response to chemotherapy, and inferior outcome.
[Mh] Termos MeSH primário: Neoplasias da Medula Óssea/genética
Proteínas de Fusão Oncogênicas/genética
Proteínas Proto-Oncogênicas c-ets/genética
Proteínas Repressoras/genética
Translocação Genética
Proteínas Supressoras de Tumor/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Neoplasias da Medula Óssea/patologia
Cromossomos Humanos Par 12
Cromossomos Humanos Par 13
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (ETS translocation variant 6 protein); 0 (MN1 protein, human); 0 (Oncogene Proteins, Fusion); 0 (Proto-Oncogene Proteins c-ets); 0 (Repressor Proteins); 0 (Tumor Suppressor Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171224
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3208-2


  3 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245317
[Au] Autor:Dong P; Tian R; Li L; Su M
[Ad] Endereço:Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, P.R. China.
[Ti] Título:Bone marrow necrosis secondary to metastatic adenocarcinoma revealed by 18F-FDG PET/CT: A clinical case report.
[So] Source:Medicine (Baltimore);96(49):e9067, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Bone marrow necrosis (BMN) is a rare malignancy-associated hematologic disorder characterized by necrosis of myeloid and stromal marrow elements with preservation of cortical bone. PATIENT CONCERNS: A 43-year-old female complaining of dizziness and vaginal bleeding for more than 2 months was presented to our department. DIAGNOSIS: Due to the laboratory test results, radiographic findings, especially F-fluoro-2-deoxy-D-glucose (F-FDG) positron emission tomography/computed tomography (PET/CT) which revealed that bone marrow was characterized by diffuse F-FDG uptake with extensive central photopenia, and pathologic results, she was diagnosed with metastatic adenocarcinoma accompanied with BMN. And the cancer most likely originated from reproductive system or breast. INTERVENTIONS: There was no effective interventions for her before knowing the accurate origin of adenocarcinoma. OUTCOMES: Two weeks later, unfortunately, she died. LESSONS: F-FDG PET/CT is a useful diagnostic modality in patients with BMN. Malignant tumor should always be considered in patients with extensive BMN, even in young people.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico por imagem
Adenocarcinoma/patologia
Neoplasias da Medula Óssea/diagnóstico por imagem
Neoplasias da Medula Óssea/patologia
Neoplasias Primárias Desconhecidas/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/patologia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
[Mh] Termos MeSH secundário: Adulto
Evolução Fatal
Feminino
Fluordesoxiglucose F18
Seres Humanos
Necrose
Compostos Radiofarmacêuticos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009067


  4 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28921546
[Au] Autor:Rifatbegovic F; Frech C; Abbasi MR; Taschner-Mandl S; Weiss T; Schmidt WM; Schmidt I; Ladenstein R; Ambros IM; Ambros PF
[Ad] Endereço:Department of Tumor Biology, Children's Cancer Research Institute (CCRI), Vienna, Austria.
[Ti] Título:Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression.
[So] Source:Int J Cancer;142(2):297-307, 2018 Jan 15.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neuroblastoma is the most common extracranial solid tumor in childhood. The vast majority of metastatic (M) stage patients present with disseminated tumor cells (DTCs) in the bone marrow (BM) at diagnosis and relapse. Although these cells represent a major obstacle in the treatment of neuroblastoma patients, insights into their expression profile remained elusive. The present RNA-Seq study of stage 4/M primary tumors, enriched BM-derived diagnostic and relapse DTCs, as well as the corresponding BM-derived mononuclear cells (MNCs) from 53 patients revealed 322 differentially expressed genes in DTCs as compared to the tumors (q < 0.001, |log FC|>2). Particularly, the levels of transcripts encoded by mitochondrial DNA were elevated in DTCs, whereas, for example, genes involved in angiogenesis were downregulated. Furthermore, 224 genes were highly expressed in DTCs and only slightly, if at all, in MNCs (q < 8 × 10 log FC > 6). Interestingly, we found the transcriptome of relapse DTCs largely resembling those of diagnostic DTCs with only 113 differentially expressed genes under relaxed cut-offs (q < 0.01, |log FC|>0.5). Notably, relapse DTCs showed a positional enrichment of 31 downregulated genes on chromosome 19, including five tumor suppressor genes: SIRT6, BBC3/PUMA, STK11, CADM4 and GLTSCR2. This first RNA-Seq analysis of neuroblastoma DTCs revealed their unique expression profile in comparison to the tumors and MNCs, and less pronounced differences between diagnostic and relapse DTCs. The latter preferentially affected downregulation of genes encoded by chromosome 19. As these alterations might be associated with treatment failure and disease relapse, further functional studies on DTCs should be considered.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/genética
Neoplasias da Medula Óssea/genética
Sequenciamento de Nucleotídeos em Larga Escala/métodos
Células Neoplásicas Circulantes/metabolismo
Neuroblastoma/genética
Transcriptoma
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/sangue
Neoplasias da Medula Óssea/sangue
Neoplasias da Medula Óssea/secundário
Progressão da Doença
Seres Humanos
Células Neoplásicas Circulantes/patologia
Neuroblastoma/sangue
Neuroblastoma/patologia
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170919
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.31053


  5 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471719
[Au] Autor:Park JR; Bagatell R; Cohn SL; Pearson AD; Villablanca JG; Berthold F; Burchill S; Boubaker A; McHugh K; Nuchtern JG; London WB; Seibel NL; Lindwasser OW; Maris JM; Brock P; Schleiermacher G; Ladenstein R; Matthay KK; Valteau-Couanet D
[Ad] Endereço:Julie R. Park, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA; Rochelle Bagatell and John M. Maris, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA; Susan L. Cohn, University of Chicago, Chicago, IL; An
[Ti] Título:Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
[So] Source:J Clin Oncol;35(22):2580-2587, 2017 Aug 01.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose More than two decades ago, an international working group established the International Neuroblastoma Response Criteria (INRC) to assess treatment response in children with neuroblastoma. However, this system requires modification to incorporate modern imaging techniques and new methods for quantifying bone marrow disease that were not previously widely available. The National Cancer Institute sponsored a clinical trials planning meeting in 2012 to update and refine response criteria for patients with neuroblastoma. Methods Multidisciplinary investigators from 13 countries reviewed data from published trials performed through cooperative groups, consortia, and single institutions. Data from both prospective and retrospective trials were used to refine the INRC. Monthly international conference calls were held from 2011 to 2015, and consensus was reached through review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeting leadership council. Results Overall response in the revised INRC will integrate tumor response in the primary tumor, soft tissue and bone metastases, and bone marrow. Primary and metastatic soft tissue sites will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine-123 ( I) -metaiodobenzylguanidine (MIBG) scans or [ F]fluorodeoxyglucose-positron emission tomography scans if the tumor is MIBG nonavid. I-MIBG scans, or [ F]fluorodeoxyglucose-positron emission tomography scans for MIBG-nonavid disease, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessment. Bone marrow will be assessed by histology or immunohistochemistry and cytology or immunocytology. Bone marrow with ≤ 5% tumor involvement will be classified as minimal disease. Urinary catecholamine levels will not be included in response assessment. Overall response will be defined as complete response, partial response, minor response, stable disease, or progressive disease. Conclusion These revised criteria will provide a uniform assessment of disease response, improve the interpretability of clinical trial results, and facilitate collaborative trial designs.
[Mh] Termos MeSH primário: Neoplasias da Medula Óssea/diagnóstico
Neoplasias da Medula Óssea/patologia
Neoplasias Ósseas/diagnóstico por imagem
Neuroblastoma/diagnóstico por imagem
Tomografia por Emissão de Pósitrons
Neoplasias de Tecidos Moles/diagnóstico por imagem
[Mh] Termos MeSH secundário: 3-Iodobenzilguanidina
Neoplasias da Medula Óssea/química
Neoplasias da Medula Óssea/secundário
Neoplasias Ósseas/secundário
Consenso
Fluordesoxiglucose F18
Seres Humanos
Imuno-Histoquímica
Neuroblastoma/secundário
Neuroblastoma/terapia
Compostos Radiofarmacêuticos
Critérios de Avaliação de Resposta em Tumores Sólidos
Neoplasias de Tecidos Moles/secundário
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE, NIH; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 35MRW7B4AD (3-Iodobenzylguanidine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171126
[Lr] Data última revisão:
171126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2016.72.0177


  6 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679734
[Au] Autor:Papo M; Diamond EL; Cohen-Aubart F; Emile JF; Roos-Weil D; Gupta N; Durham BH; Ozkaya N; Dogan A; Ulaner GA; Rampal R; Kahn JE; Sené T; Charlotte F; Hervier B; Besnard C; Bernard OA; Settegrana C; Droin N; Hélias-Rodzewicz Z; Amoura Z; Abdel-Wahab O; Haroche J
[Ad] Endereço:Service de Médecine Interne 2, Institut E3M, Centre de Références des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Histiocytoses, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
[Ti] Título:High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.
[So] Source:Blood;130(8):1007-1013, 2017 Aug 24.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects adults and is driven by a high frequency of mutations in , , and kinases promoting MAPK signaling. Because of the relative rarity of ECD, key clinical features of the disease may not be well defined. Across a multi-institutional cohort of 189 patients with ECD and ECD overlapping with Langerhans cell histiocytosis (so-called mixed histiocytosis [MH]), we identified an unexpected and heretofore undescribed frequent occurrence of myeloid neoplasms among patients with ECD and MH. Some 10.1% (19/189) of patients with ECD have an overlapping myeloid neoplasm, most commonly occurring as a myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), or mixed MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia). Consistent with this, molecular analysis frequently detected hallmark driver mutations of myeloid neoplasms (such as V617F and mutations) coexisting with those characteristic of histiocytosis (such as V600E and mutations). Histiocytosis patients diagnosed with a concomitant myeloid malignancy were significantly older at diagnosis and more commonly presented with MH than those without a myeloid malignancy. In some cases, the presence of distinct kinase mutations in the histiocytosis and myeloid neoplasm resulted in discordant and adverse responses to kinase-directed targeted therapies. These data highlight the clinical importance of evaluating adults with histiocytosis for a concomitant myeloid neoplasm.
[Mh] Termos MeSH primário: Neoplasias da Medula Óssea/complicações
Neoplasias da Medula Óssea/epidemiologia
Histiocitose de Células não Langerhans/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Doença de Erdheim-Chester/complicações
Feminino
Seres Humanos
Masculino
Meia-Idade
Terapia de Alvo Molecular
Prevalência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-01-761718


  7 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28582813
[Au] Autor:Chang YS; Huang JS; Yen CL; Chien RN; Wang CH; Lai CH; Wu TH; Lan YJ; Yeh KY
[Ad] Endereço:Division of Hemato-oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung and Chang Gung University, College of Medicine, Taiwan.
[Ti] Título:Body mass index above 24 is beneficial for the 6-month survival rate in hepatocellular carcinoma patients with extrahepatic metastases.
[So] Source:Asia Pac J Clin Nutr;26(4):637-641, 2017.
[Is] ISSN:0964-7058
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: To investigate the effect of overweight status on the 6-month survival rate in patients with extrahepatic hepatocellular carcinoma (HCC). METHODS AND STUDY DESIGN: We retrospectively analyzed the records of 51 patients with hepatocellular carcinoma and extrahepatic metastases between 2007 and 2010 before treatment. The associations among overweight status (body mass index [BMI] >24 kg/m2), demographic variables, and survival outcome were analyzed by univariate and multivariate analysis. RESULTS: BMI>24 kg/m2 was significantly associated with the 6-month survival rate (p=0.042). Gender (p=0.149), Child Pugh classification (p=0.149), Okuda staging (p=0.093), and albumin concentration >3.5 mg/dL (p=0.082) showed marginal survival benefits in univariate analysis. Multivariate analysis confirmed that BMI >24 kg/m2 was an independent prognostic factor for the 6-month survival rate (p=0.03). CONCLUSIONS: BMI >24 kg/m2 was associated with an improved 6-month survival rate in patients with extrahepatic metastatic hepatocellular carcinoma.
[Mh] Termos MeSH primário: Índice de Massa Corporal
Carcinoma Hepatocelular/patologia
Neoplasias Hepáticas/patologia
[Mh] Termos MeSH secundário: Neoplasias das Glândulas Suprarrenais/secundário
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Medula Óssea/secundário
Neoplasias Ósseas/secundário
Neoplasias Encefálicas/secundário
Feminino
Seres Humanos
Neoplasias Pulmonares/secundário
Linfonodos/patologia
Masculino
Meia-Idade
Neoplasias Pancreáticas/secundário
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.6133/apjcn.062016.03


  8 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28502479
[Au] Autor:Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
[Ad] Endereço:School of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
[Ti] Título:Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
[So] Source:Am J Pathol;187(7):1512-1522, 2017 Jul.
[Is] ISSN:1525-2191
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Myeloproliferative neoplasms (MPNs) are a group of related clonal hemopoietic stem cell disorders associated with hyperproliferation of myeloid cells. They are driven by mutations in the hemopoietic stem cell, most notably JAK2 , CALR, and MPL. Clinically, they have the propensity to progress to myelofibrosis and transform to acute myeloid leukemia. Megakaryocytic hyperplasia with abnormal features are characteristic, and it is thought that these cells stimulate and drive fibrotic progression. The biological defects underpinning this remain to be explained. In this study we examined the megakaryocyte genome in 12 patients with MPNs to determine whether there are somatic variants and whether there is any association with marrow fibrosis. We performed targeted next-generation sequencing for 120 genes associated with myeloid neoplasms on megakaryocytes isolated from aspirated bone marrow. Ten of the 12 patients had genomic defects in megakaryocytes that were not present in nonmegakaryocytic hemopoietic marrow cells from the same patient. The greatest allelic burden was in patients with increased reticulin deposition. The megakaryocyte-unique mutations were predominantly in genes that regulate chromatin remodeling, chromosome alignment, and stability. These findings show that genomic abnormalities are present in megakaryocytes in MPNs and that these appear to be associated with progression to bone marrow fibrosis.
[Mh] Termos MeSH primário: Neoplasias da Medula Óssea/genética
Leucemia Mieloide Aguda/genética
Transtornos Mieloproliferativos/genética
Mielofibrose Primária/genética
[Mh] Termos MeSH secundário: Alelos
Medula Óssea/patologia
Neoplasias da Medula Óssea/patologia
Frequência do Gene
Genômica
Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Janus Quinase 2/genética
Leucemia Mieloide Aguda/patologia
Megacariócitos/patologia
Mutação
Células Mieloides/patologia
Transtornos Mieloproliferativos/patologia
Mielofibrose Primária/patologia
Receptores de Trombopoetina/genética
Análise de Sequência de DNA
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Thrombopoietin); 143641-95-6 (MPL protein, human); EC 2.7.10.2 (JAK2 protein, human); EC 2.7.10.2 (Janus Kinase 2)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE


  9 / 1568 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28346666
[Au] Autor:Cook RW; Abraham LA; McCowan CI
[Ad] Endereço:Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Victoria, Australia.
[Ti] Título:Disseminated peripheral neuroblastoma in a Rhodesian Ridgeback dog.
[So] Source:Aust Vet J;95(4):129-133, 2017 Apr.
[Is] ISSN:1751-0813
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CASE REPORT: A 4-year-old neutered male Rhodesian Ridgeback dog with right-sided Horner's syndrome, bilateral laryngeal paralysis, neck pain and bilateral hindlimb ataxia was euthanased following deterioration of its neurological status. Necropsy examination revealed an off-white retropharyngeal neoplastic mass (100 × 30 × 30 mm) attached to the base of the skull on the right side and macroscopic nodular metastases in the spleen and three vertebral bodies (C6, C7 and T6), including a nodule attached to the dura at C7. Histological evidence of neuroblastic tumour was detected in these macroscopic lesions, a regional lymph node, bone marrow of a femur and all 15 vertebral bodies (C1-T8) examined, including the three with macroscopic metastases, and in the lumens of small blood vessels in the lungs and liver. Ganglion cell differentiation was detected only in the primary retropharyngeal mass, one splenic nodule and the C7 dural nodule. Neoplastic cells were immunoreactive to neurofilament protein (ganglion cells only), vimentin and synaptophysin, and were negative for S100 protein, GFAP, CD3 and Pax5. CONCLUSION: The diagnosis was disseminated peripheral neuroblastoma, differentiating subtype (International Neuroblastoma Pathology Classification), with likely primary involvement of the right cranial cervical ganglion. This appears to be the first report of neuroblastoma in a dog with widespread occult haematogenous metastasis to bone marrow.
[Mh] Termos MeSH primário: Doenças do Cão/patologia
Neuroblastoma/veterinária
Neoplasias do Sistema Nervoso Periférico/veterinária
[Mh] Termos MeSH secundário: Animais
Ataxia/etiologia
Ataxia/veterinária
Neoplasias da Medula Óssea/secundário
Neoplasias da Medula Óssea/veterinária
Neoplasias Ósseas/secundário
Neoplasias Ósseas/veterinária
Cães
Síndrome de Horner/etiologia
Síndrome de Horner/veterinária
Masculino
Neuroblastoma/complicações
Neuroblastoma/patologia
Neoplasias do Sistema Nervoso Periférico/complicações
Neoplasias do Sistema Nervoso Periférico/patologia
Neoplasias Esplênicas/secundário
Neoplasias Esplênicas/veterinária
Paralisia das Pregas Vocais/etiologia
Paralisia das Pregas Vocais/veterinária
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170612
[Lr] Data última revisão:
170612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1111/avj.12565


  10 / 1568 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28315904
[Au] Autor:Lee JW; Lee SC; Kim HJ; Lee SM
[Ad] Endereço:Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Korea. gareen@naver.com.
[Ti] Título:Prognostic value of bone marrow F-FDG uptake on PET/CT in lymphoma patients with negative bone marrow involvement.
[So] Source:Hell J Nucl Med;20(1):17-25, 2017 Jan-Apr.
[Is] ISSN:1790-5427
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The study evaluated the significance of 18F fluorodeoxyglucose ( F-FDG) uptake of bone marrow (BM) for predicting progression-free survival (PFS) in lymphoma patients without BM involvement. SUBJECTS AND METHODS: Ninety-five patients with histopathologically proven lymphoma, 7 Hodgkin's lymphoma and 88 non-Hodgkin's lymphoma, who underwent F-FDG positron emission tomography/computed tomography (PET/CT) and BM biopsy for staging work-up and 40 normal subjects were retrospectively enrolled. Maximal F-FDG uptake of lymphoma (Lmax), mean F-FDG uptake of BM (BM SUV) and BM-to-liver uptake ratio (BLR) were measured. Prognostic value of BM SUV and BLR for predicting PFS were assessed. RESULTS: Of the 95 patients, 35 (36.8%) were histopathologically or clinically diagnosed with BM involvement of lymphoma. There were significant differences of BLR among lymphoma patients with/without BM involvement and normal subjects (P<0.05). For all patients, high risk indicated by International Prognostic Index (IPI) score and Lmax were significantly associated with PFS on multivariate analysis (P<0.05). For 60 patients without BM involvement, BM SUV and BLR were independent prognostic factors for PFS along with performance status and Lmax (p<0.05). Among patients without BM involvement, high F-FDG uptake of BM was associated with significantly worse PFS than low F-FDG uptake of BM, with no significant difference in PFS apparent compared to patients with BM involvement. CONCLUSION: In lymphoma patients without BM involvement, F-FDG uptake of BM was significantly associated with worse PFS. Patients with high F-FDG uptake of BM showed similar prognosis to those with BM involvement.
[Mh] Termos MeSH primário: Neoplasias da Medula Óssea/diagnóstico por imagem
Neoplasias da Medula Óssea/mortalidade
Medula Óssea/diagnóstico por imagem
Linfoma/mortalidade
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Distribuição por Idade
Idoso
Medula Óssea/metabolismo
Neoplasias da Medula Óssea/metabolismo
Comorbidade
Intervalo Livre de Doença
Feminino
Fluordesoxiglucose F18/farmacocinética
Seres Humanos
Linfoma/diagnóstico por imagem
Linfoma/metabolismo
Masculino
Meia-Idade
Prevalência
Prognóstico
Compostos Radiofarmacêuticos/farmacocinética
Reprodutibilidade dos Testes
República da Coreia/epidemiologia
Fatores de Risco
Sensibilidade e Especificidade
Distribuição por Sexo
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170320
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910502



página 1 de 157 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde